Lv51
1090 积分 2024-01-12 加入
Maintenance immunosuppression in myasthenia gravis, an update
12天前
已完结
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of 2 different treatment approaches
16天前
已完结
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees
1个月前
已完结
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
2个月前
已完结
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
3个月前
已完结
Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect
4个月前
已完结
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
4个月前
已完结
Belimumab treatment of adult idiopathic inflammatory myopathy
7个月前
已关闭
Belimumab treatment of adult idiopathic inflammatory myopathy
7个月前
已完结
Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study
8个月前
已完结
皖公网安备34019202002308
